Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $30.25

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been assigned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $30.25.

Several research analysts have commented on MLTX shares. Stifel Nicolaus cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price for the company. in a report on Monday, September 29th. HC Wainwright reduced their price target on shares of MoonLake Immunotherapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, November 21st. BTIG Research lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating and set a $85.00 price objective for the company. in a research note on Monday, September 29th. Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research note on Tuesday, September 30th. Finally, Needham & Company LLC reduced their target price on MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 30th.

MoonLake Immunotherapeutics Trading Down 3.5%

MoonLake Immunotherapeutics stock opened at $13.21 on Friday. The firm has a market cap of $848.48 million, a price-to-earnings ratio of -3.98 and a beta of 1.21. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The firm’s 50 day moving average price is $12.65 and its two-hundred day moving average price is $33.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period last year, the company earned ($0.56) earnings per share. On average, research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kristian Reich sold 130,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the transaction, the insider owned 72,908 shares in the company, valued at $1,099,452.64. This represents a 64.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 402,908 shares of company stock worth $5,987,162 over the last three months. 12.05% of the stock is owned by insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of MoonLake Immunotherapeutics by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after buying an additional 559 shares during the last quarter. Squarepoint Ops LLC raised its position in MoonLake Immunotherapeutics by 3.7% during the second quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock valued at $829,000 after acquiring an additional 629 shares in the last quarter. MPM Bioimpact LLC raised its position in MoonLake Immunotherapeutics by 0.3% during the first quarter. MPM Bioimpact LLC now owns 316,049 shares of the company’s stock valued at $12,348,000 after acquiring an additional 819 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after acquiring an additional 1,158 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in MoonLake Immunotherapeutics by 7.3% in the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock valued at $987,000 after acquiring an additional 1,425 shares during the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.